722538-98-9Relevant articles and documents
-
-
, (2022/01/12)
Compounds of formula (I) useful as tyrosine kinase 2 (Tyk2) inhibitors, pharmaceutical compositions containing these compounds, methods of using the pharmaceutical compositions in the treatment of various disorders related to the regulation of Tyk2 activi
TYK2 INHIBITORS AND USES THEREOF
-
, (2020/06/10)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Wrobleski, Stephen T.,Moslin, Ryan,Lin, Shuqun,Zhang, Yanlei,Spergel, Steven,Kempson, James,Tokarski, John S.,Strnad, Joann,Zupa-Fernandez, Adriana,Cheng, Lihong,Shuster, David,Gillooly, Kathleen,Yang, Xiaoxia,Heimrich, Elizabeth,McIntyre, Kim W.,Chaudhry, Charu,Khan, Javed,Ruzanov, Max,Tredup, Jeffrey,Mulligan, Dawn,Xie, Dianlin,Sun, Huadong,Huang, Christine,D'Arienzo, Celia,Aranibar, Nelly,Chiney, Manoj,Chimalakonda, Anjaneya,Pitts, William J.,Lombardo, Louis,Carter, Percy H.,Burke, James R.,Weinstein, David S.
, p. 8973 - 8995 (2019/11/14)
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formi
